PDF下载 ( 1544 KB)
Research advances in treatment of non-alcoholic fatty liver disease
-
摘要:
发达国家约1/3人口患有非酒精性脂肪性肝病(NAFLD),其中10%~30%的NAFLD表现为非酒精性脂肪性肝炎(NASH)。NAFLD和心血管疾病有共同的代谢危险因素,因此NASH患者肝脏及心血管相关病死率明显增加。主要从改善生活方式、减肥治疗、针对代谢综合征的治疗、胰岛素增敏剂、抗氧化剂类药物治疗及终末期肝病的治疗5个方面介绍了NAFLD的治疗进展。指出了临床医生在NAFLD诊治过程中应更多关注NAFLD伴发的代谢综合征。
Abstract:Non- alcoholic fatty liver disease( NAFLD) affects up to a third of the population in developed countries. Between 10% and30% of patients with NAFLD have non- alcoholic steatohepatitis( NASH). There are metabolic risk factors common to both NAFLD and cardiovascular disease,so patients with NASH have an increased risk of liver- related and cardiovascular death. This articles reviews the most recent advances in the management of NAFLD in five main areas: lifestyle modification,weight loss treatment,therapy for metabolic syndrome,insulin sensitizer and antioxidant pharmacotherapy,and management of end- stage liver disease. It is pointed out that clinicians need to pay more attention to metabolic syndrome in the diagnosis and treatment of NAFLD.
-
Key words:
- fatty liver /
- therapy /
- review
-
本文二维码
计量
- 文章访问数: 2654
- HTML全文浏览量: 8
- PDF下载量: 575
- 被引次数: 0
下载:
